Progress of immunotherapy for NK/T cell leukemia/lymphoma

VernacularTitle:NK/T细胞白血病/淋巴瘤免疫治疗的研究进展
Author: Qiannan YANG ¹ ; Jinyan XIAO ; Yang XU ; Depei WU
Author Information

1. 国家血液系统疾病临床医学研究中心　江苏省血液研究所　苏州大学附属第一医院　国家卫生健康委员会血栓与止血重点研究室，苏州　215006
Keywords: Lymphoma, extranodal, NK-T cell; Immunotherapy; Chimeric antigen receptor T-cells
From: Journal of Leukemia & Lymphoma 2023;32(9):565-569
CountryChina
Language:Chinese
Abstract: NK/T cell leukemia/lymphoma is a type of malignancy originating from T cells or natural killer cells with low incidence and poor clinical prognosis. There is still no effective treatment strategy. In recent years, targeted therapy has made great progress in the treatment of hematological malignancies, including monoclonal antibody and chimeric antigen receptor T cells (CAR-T), among which CD30, CD7, CD5, CD52, CCR4 and other target antigens are effective in the treatment of NK/T cell leukemia/lymphoma, but its widespread application still faces a great challenge. This article reviews the progress of immunotherapy for NK/T cell leukemia/lymphoma.